Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTLF FitLife Brands	$14.00 -2.0%	$14.09	$9.83 ▼ $17.75	$131.47M	0.81	17,635 shs	9,546 shs
GLSI Greenwich LifeSciences	$9.20 -2.9%	$9.63	$8.06 ▼ $18.75	$122.99M	1.69	46,730 shs	23,025 shs
LVTX LAVA Therapeutics	$1.31	$1.27	$0.85 ▼ $2.39	$34.46M	0.48	157,856 shs	6,986 shs
NKTX Nkarta	$1.86 -2.6%	$1.85	$1.31 ▼ $8.23	$131.98M	0.72	1.06 million shs	458,497 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTLF FitLife Brands	0.00%	-2.17%	-3.18%	+0.36%	-7.89%
GLSI Greenwich LifeSciences	0.00%	-4.76%	-5.06%	-23.33%	-35.66%
LVTX LAVA Therapeutics	0.00%	-0.76%	+3.97%	+0.77%	-42.79%
NKTX Nkarta	0.00%	-2.11%	+8.14%	+12.05%	-70.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FTLF FitLife Brands	4.1608 of 5 stars	3.7	3.0	1.9	3.3	3.1
GLSI Greenwich LifeSciences	2.2397 of 5 stars	3.5	1.0	2.7	3.3	0.0
LVTX LAVA Therapeutics	2.1992 of 5 stars	3.0	5.0	2.2	0.0	0.6
NKTX Nkarta	3.6346 of 5 stars	4.6	3.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTLF FitLife Brands	3.33	Buy	$20.50	46.43% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	323.91% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside
NKTX Nkarta	3.13	Buy	$14.33	670.61% Upside

Current Analyst Ratings Breakdown

Latest LVTX, FTLF, NKTX, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50
3/27/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
3/27/2025	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/17/2025	FTLF FitLife Brands	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTLF FitLife Brands	$63.86M	2.06	$0.73 per share	19.05	$3.04 per share	4.61
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.52 per share	N/A
LVTX LAVA Therapeutics	$4.99M	6.91	N/A	N/A	$1.95 per share	0.67
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTLF FitLife Brands	$5.30M	$0.84	16.57	12.73	N/A	13.38%	28.03%	15.13%	N/A
GLSI Greenwich LifeSciences	-$8.89M	-$1.26	N/A	N/A	N/A	N/A	-185.12%	-164.27%	8/12/2025 (Estimated)
LVTX LAVA Therapeutics	-$41.97M	-$1.04	N/A	N/A	N/A	N/A	-62.22%	-29.37%	8/19/2025 (Estimated)
NKTX Nkarta	-$117.50M	-$1.51	N/A	N/A	N/A	N/A	-27.13%	-21.67%	8/12/2025 (Estimated)

Latest LVTX, FTLF, NKTX, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTLF FitLife Brands	0.28	1.50	0.64
GLSI Greenwich LifeSciences	N/A	6.91	6.91
LVTX LAVA Therapeutics	N/A	5.36	5.36
NKTX Nkarta	N/A	12.91	12.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTLF FitLife Brands	2.32%
GLSI Greenwich LifeSciences	4.16%
LVTX LAVA Therapeutics	N/A
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
FTLF FitLife Brands	61.30%
GLSI Greenwich LifeSciences	51.67%
LVTX LAVA Therapeutics	9.50%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTLF FitLife Brands	20	9.39 million	3.56 million	Not Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.35 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	26.08 million	Optionable
NKTX Nkarta	140	70.96 million	64.43 million	Optionable

LVTX, FTLF, NKTX, and GLSI Headlines

Recent News About These Companies

Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $14.00

June 12 at 1:55 AM | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

June 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

Bank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

June 8, 2025 | marketbeat.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 8, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.com

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

May 28, 2025 | marketbeat.com

BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX)

May 26, 2025 | marketbeat.com

AWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)

May 23, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for Nkarta FY2025 Earnings

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Acquires 1,643,719 Shares of Nkarta, Inc. (NASDAQ:NKTX)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Lower Earnings Estimates for Nkarta

May 20, 2025 | marketbeat.com

William Blair Comments on Nkarta's Q2 Earnings (NASDAQ:NKTX)

May 20, 2025 | marketbeat.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Dimensional Fund Advisors LP Has $1.42 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

May 18, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of "Buy" by Analysts

May 18, 2025 | marketbeat.com

Bridgeway Capital Management LLC Has $50,000 Position in Nkarta, Inc. (NASDAQ:NKTX)

May 16, 2025 | marketbeat.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, FTLF, NKTX, and GLSI Company Descriptions

FitLife Brands NASDAQ:FTLF

$14.00 -0.28 (-1.96%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$13.88 -0.12 (-0.86%)

As of 06/13/2025 04:04 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Greenwich LifeSciences NASDAQ:GLSI

$9.20 -0.27 (-2.85%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.23 +0.03 (+0.33%)

As of 06/13/2025 05:17 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

LAVA Therapeutics NASDAQ:LVTX

$1.31 0.00 (0.00%)

Closing price 06/13/2025 03:58 PM Eastern

Extended Trading

$1.30 -0.01 (-0.76%)

As of 06/13/2025 04:38 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Nkarta NASDAQ:NKTX

$1.86 -0.05 (-2.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.81%)

As of 06/13/2025 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time